Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Mbelele PM, Mbelele PM, Mpolya EA, Sauli E, Mtafya B, et al.
…erculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether Mycobacterium tuberculosis killing rates measured by tuberculosis mo…
Wenhong Zhang, Dr.
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifa…
Padmapriyadarsini Chandrasekharan
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models o…
Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew Zimmerman, Véronique Dartois, et al.
…rine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquilin…
Malaisamy Muniyandi, Nagarajan Karikalan, Banurekha Velayutham, Kavitha Rajsekar, Chandrasekaran Padmapriyadarsini
Abstract Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in I…
Alexander Berg, James Clary, Debra Hanna, Eric L. Nuermberger, Anne J. Lenaerts, et al.
…necessitating the development of new and improved treatment regimens. Non-clinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in pro…
Ajay Gupta
…torically required long, toxic, and operationally demanding regimens–often extending beyond 18 months and associated with treatment fatigue, high default rates, and severe adverse effects. Against this background, the World Health Organization recommended the all-oral, 6-month BP…
Rivaldo Heru Setiawan
…) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, pretomanid, and linezolid), have emerged as promising alternatives…
Feng Z, Miao Y, Peng Y, Sun F, Zhang Y, et al.
…. There is an urgent need to simplify and shorten treatment regimens to reduce interruption and adverse event rates, improve compliance, and reduce costs. Methods ORIENT is a multicenter, randomized controlled, open-label, phase II/III, non-inferiority trial involving DS-TB patie…
David Branigan, Claudia M. Denkinger, Jennifer Furin, Petra Heitkamp, Stijn Deborggraeve, et al.
…s to implement the shortest and best available tuberculosis regimens—1 month or once-weekly for tuberculosis prevention, 4 months for drug-sensitive tuberculosis, and 6 months for drug-resistant tuberculosis—by the end of 2024.1McKenna L Frick M Angami K et al.The 1/4/6x24 campai…
Zheng X, Gui X, Yao L, Ma J, He Y, et al.
… the capacity of the short-course approach to identify drug regimens that can shorten the treatment time for tuberculosis.
Rupani MP, Dave JD, Parmar VB, Singh MP, Parikh KD
…iscontinuation of multidrug-resistant tuberculosis (MDR-TB) regimens have not been studied in Gujarat. We aimed to find out the adverse drug reactions (ADRs) and predictors for discontinuation of MDR-TB regimens. Methods We conducted this cross-sectional study in Bhavnagar distri…
Arnold Louie, Michael Neely, Sarah Kim, Charles A Scanga, JoAnne L Flynn, et al.
… There has been little prior effort to identify combination regimens that employ new or repurposed drugs in a rational way. **METHODS AND FINDINGS:** Our group developed a pathway to combine agents to achieve this end. This pathway starts with standard baseline evaluations (e.g.…
Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, et al.
…llected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon. OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin (LVX) based STR on bact…
Singhal KK, Shinde M
…acceptability of ATT. The available "short-course treatment regimens" are still relatively long, thereby adversely affecting treatment compliance. There is a need for effective, safe, short and intensive regimens for TB which can reduce the treatment cost and adverse effects, the…
Soni H, Kumar-M P, Mishra S, Bellam BL, Singh H, et al.
…jective : To compare risk of hepatotoxicity between various regimens for reintroduction of antitubercular therapy (ATT) in patients with previous episode of ATT hepatitis. Methods : We searched various databases (PubMed, Embase, CENTRAL, Scopus, WoS and LILACS) for studies compar…
Budak M, Via LE, Weiner DM, Barry CE 3rd, Nanda P, et al.
…nization has focused goals of shortening standard treatment regimens for TB in their End TB Strategy efforts, which aim to reduce TB-related deaths by 95% by 2035. For this purpose, many novel and promising combination antibiotics are being explored that have recently been discov…
Jindani A, Atwine D, Grint D, Bah B, Adams J, et al.
BACKGROUND: Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid and secure lung sterilization and may enable shorter tuberculosis treatment regimens. METHODS: We …
Rich ML, Khan U, Zeng C, LaHood A, Franke MF, et al.
…ness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited. OBJECTIVES: To report end-of-treatment outcomes for MDR/RR-TB patients from a 2015-2018 multi-country cohort that received a regimen consistent w…
Nusrat Shafiq, Ashok Kumar, Vikram Vohra, Gopal Krishan Khuller, Manjula Singh, et al.
**BACKGROUND:** Clofazimine, an antimycobacterial agent, has demonstrated efficacy in reducing the treatment duration for MDR TB. **OBJECTIVES:** To determine whether a 16 week clofazimine-based regimen is non-inferior to the standard 24 week regimen for drug-susceptible pulmona…
Josephine G R Simanjuntak, Made A K Gandhy, Kynthia Sadha
…y in high- burden regions like Indonesia. Shorter treatment regimens have been proposed to improve outcomes for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). This systematic review and Bayesian network meta-analysis aimed to evaluate the efficacy and safety of the…
Berg A, Clary J, Hanna D, Nuermberger E, Lenaerts A, et al.
…necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the …
Vibol Iem, Sakhone Suthepmany, Vongkham Inthavong, Anousone Sisouvanh, Khamloun Choumlivong, et al.
…is (MDR/RR-TB) was introduced under the TDR Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis (ShORRT) initiative. **METHODS:** A retrospective and prospective comparative cohort study was conducted across five drug-resistant tuberculosis treatment centres from Janu…
Malaisamy Muniyandi, Karikalan Nagarajan, Karthick Chelvanayagam, Kavitha Rajsekar, Kirti Tyagi, et al.
…s resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquilin…
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, et al.
…rine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquilin…